Analyst firms · J.P. Morgan · AVIR

J.P. Morgan AVIR price target and rating history

Atea Pharmaceuticals Inc. (AVIR) · Health Care

J.P. Morgan rates Atea Pharmaceuticals Inc. (AVIR) Underweight with a $8 price target, as of its latest action on Aug 10, 2023. It has published 3 rating actions on AVIR since October 2021, including 0 upgrades and 2 downgrades.

Current rating
Underweight
Price target
$8
Median target, all firms
Too few
Actions on AVIR
3

J.P. Morgan price target on AVIR

$16$12$820222023202420252026
J.P. Morgan price target on AVIR, each point a stated target, October 2021 to March 2022.

Every J.P. Morgan rating on AVIR

Questions about J.P. Morgan and AVIR

What is J.P. Morgan's price target for AVIR?
J.P. Morgan's latest stated price target for Atea Pharmaceuticals Inc. (AVIR) is $8, from its action on Mar 2, 2022.
What is J.P. Morgan's rating on AVIR?
J.P. Morgan rates AVIR Underweight, a bearish rating, as of Aug 10, 2023.
When did J.P. Morgan last change its view on AVIR?
On Aug 10, 2023, J.P. Morgan downgrades to Underweight from Neutral.

More AVIR rating histories

All J.P. Morgan ratingsAVIR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.